Guidelines for controlled trials of drugs in migraine: Second edition

Cephalalgia

Volumn 20, Issue 9, 2000, Pages 765-786

  Tfelt Hansen, P ^a,b   Block, G ^a   Dahlof C ^a   Diener, H C ^a   Ferrari, Md ^a   Goadsby, Pj ^a   Guidetti, V ^a   Jones, B ^a   Lipton, Rb ^a   Massiou, H ^a   Meinert, C ^a   Sandrini, G ^a   Steiner, T ^a   Winter, Pbo ^a  

^a Glostrup Hospital ^*

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIA; CONTROLLED STUDY; MIGRAINE; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY OF LIFE; RECURRENCE RISK; RELAPSE; REVIEW;

EID: 0034483344     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.2000.00117.x     Document Type: Review

References (115)

1. Guidelines for controlled trials of drugs in migraine. 1st edn.
2. Guidelines for trials of drug treatments in tension-type headache. 1st edn.
3. Guidelines for controlled trials in cluster headache. 1st edn.
4. Methodology of clinical trials of sumatriptan in migraine and cluster headache
5. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache
6. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
7. Sumatriptan. An update review of its use in migraine
8. Naratriptan
9. Zolmitriptan (ZomigTM, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: An overview of efficacy
10. Zolmitriptan: A new acute treatment for migraine
11. 1B/1D receptor agonist for the treatment of migraine
12. Rizatriptan: A review of its efficacy in the management of migraine
13. Zolmitriptan: A review of its use in migraine
14. 1B/1D receptor agonists, in the acute treatment of migraine
15. Methodological aspects of prophylactic drug trials in migraine
16. Methodological aspects of drug trials in migraine
17. Probleme und Ansätze zur Anlage und Bewertung von Therapiestudien bei Kopfschmerzpatienten
18. Methodological problems in migraine trials
19. Methodology of migraine trials
20. Headache
21. Methodologic issues in acute migraine clinical trials
22. "Menstrual" migraine: Towards a definition
23. Ethical issues in headache research and management
24. Clinical trial of nimodipine for single attacks classic migraine
25. Subcutaneous sumatriptan during the migraine aura
26. Presentation of a new diagnostic instrument: The diagnostic headache diary
27. Relationship of headache to phase of the menstrual cycle among young women: A daily diary study
28. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain
29. Problems in childhood migraine
30. Epidemiology of headache in a general population - A prevalence study
31. Prevalence and sex-ratio of the subtypes of migraine
32. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors
33. Migraine headaches: Epidemiology and comorbidity
34. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice
35. Unbalanced randomisation influences placebo response: Scientific versus ethical issues around the use of placebo in migraine trials
36. Hazard of inference: The active control investigation
37. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine
38. Triptans in migraine: A comparative review of their pharmacology, pharmacokinetics and efficacy
39. A placebo-controlled crossover study of rizatriptan in the treatment of multiple attacks
40. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine
41. Success rates of combined oral lysine acetylsalicylate and metoclopramide, oral sumatriptan, and placebo depend on initial headache severity. A preliminary retrospective analysis
42. Absorption of effervescent aspirin during migraine
43. Tolfenamic acid, Metoclopramide, caffeine and their combinations in the treatment of migraine attacks
44. 311C90 (zolmitriptan), a novel centrally and peripherally acting oral 5-hydroxytrypyamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period
45. Antiemetics, prokinetics, neuroleptic and miscellaneous drugs in the acute treatment of migraine
46. Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: A placebo-controlled study
47. Naproxen sodium in the treatment of migraine
48. Randomized double-blind comparison of tolfenamic acid and paracetamol in migraine
49. Sumatriptan - An oral dose-defining study
50. Responsiveness of non-HIS migraine and tension-type headache to sumatriptan
51. Sumatriptan for the range of headache in migraine sufferers: Results of the spectrum study
52. Determinations of patients satisfaction with migraine therapy
53. Acute migraine therapy: Do doctors understand what patients want from therapy
54. Verbal scales in the acute treatment of migraine: Semantic categories and clinical relevance
55. Complete relief (IHS' criterion) or no or mild pain ("Glaxo criterion")? Estimation of relative power in placebo-controlled clinical trials of sumatriptan
56. How to assess and compare drugs in the management of migraine: Success rates in term of response and recurrence
57. Headache pain model for assessing and comparing the efficacy of over-the-counter analgesics
58. A model to evaluate mild analgesics in oral surgery outpatients
59. Onset and duration: Measurement and analysis
60. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat
61. Time-to-event analysis, or who gets better sooner?. An emerging concept in headache study methodology
62. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine
63. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine
64. Efficacy of subcutaneous sumatriptan in repeated episodes of migraine
65. Evaluation of a multiple dose regiment of oral sumatriptan for the acute treatment of migraine
66. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo-controlled trials
67. EEC Notes for Guidance: Good Clinical Practice for Trials on Medicinal Products in the European Community
68. The International Conference on Harmonization Good Clinical Practice guideline
69. Naratriptan is effective and well tolerated in the acute treatment of migraine. Results of a double-blind, placebo-controlled crossover study
70. Efficacy definitions of migraine studies
71. Ergotamine in the acute treatment of migraine
72. Oral sumatriptan for the long-term treatment of migraine: Clinical findings
73. Confidence intervals rather than P values: Estimation rather than hypothesis testing
74. Valproate: A new drug in migraine prophylaxis
75. Efficacy of beta-blockers in migraine. A critical review
76. The role of calcium entry blockers in the prophylaxis of migraine
77. European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura)
78. Patients numbers needed in prophylactic migraine trials
79. Migraine trials: Crossover or parallel group
80. A placebo, controlled, double-blind, crossover trial of flunarizine in common migraine
81. Sodium valproate has a prophylactic effect in migraine without aura: A triple-blind, placebo-controlled crossover study
82. Migraine prophylaxis with divalproex
83. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better
84. Timolol vs propranolol vs placebo in common migraine prophylaxis
85. Clomipramine and metoprol in migraine prophylaxis - A double-blind crossover study
86. Subgroup analysis and other (mis) uses of baseline data in clinical trials
87. Assessment of health-related quality of life in migraine
88. Impact of Headache on the Individual Sufferer
89. Quantifying the burden of disease: The technical basis for disability-adjusted life years
90. Understanding DALYs (disability adjusted life years)
91. Treatment of juvenile migraine with subcutaneous sumatriptan
92. The tolerability, safety and efficacy of oral sumatriptan 50 mg and 100 mg for the acute treatment of migraine in adolescents
93. Subcutaneous sumatriptan in the clinical setting: The first fifty consecutive patients with acute migraine in a paediatric neurology office practice
94. Sumatriptan for migraine attacks in children: A randomised placebo-controlled study. Do children in migraine respond to oral sumatriptan differently from adults?
95. Oral dihydroergotamine for therapy-resistant migraine attacks in children
96. Ibruprofen or acetaminophen for the acute treatment of migraine in children: A double-blind, randomized, placebo-controlled, crossover study
97. Appropriate migraine therapy for children and adolescents
98. Intranasal sumatriptan for the acute treatment of migraine in children
99. Behavioral and prophylactic intervention studies of pediatric migraine: An exploratory meta-analysis
100. Propranolol used in prophylaxis of migraine in children
101. Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, cross-over study
102. Influence of female hormones on migraine
103. Migraine and menstruation: A pilot study
104. Naproxen sodium in menstrual migraine prophylaxis: A double-blind placebo controlled study
105. Prevention of menstrual migraine by percutaneous oestradiol
106. Menstrual migraine: A double-blind trial of percutaneous estradiol
107. Publication: An ethical imperative
108. Improving the quality of reporting of randomised controlled trials. The CONSORT Statement